Mantle cell lymphoma: Report of the 2010 Mantle Cell Lymphoma Consortium Workshop

Leukemia and Lymphoma

Volumn 52, Issue 1, 2011, Pages 24-33

  Williams, Michael E ^a   Connors, Joseph M ^b   Dreyling, Martin H ^c   Gascoyne, Randy D ^b   Kahl, Brad S ^d   Leonard, John P ^e   Press, Oliver W ^f   Wilson, Wyndham H ^g  

^a UNIVERSITY OF VIRGINIA   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive cellular therapy; Cell cycle; Immunotherapy; Mantle cell lymphoma; MicroRNA; Minimal residual disease (MRD)

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AZ 4248; BARDOXOLONE; BENDAMUSTINE; BORTEZOMIB; CANCER VACCINE; CISPLATIN; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; INTERFERON; INTERLEUKIN 2 DERIVATIVE; LENALIDOMIDE; MICRORNA; NUCLEOSIDE ANALOG; PREDNISONE; PROSTAVAX; RITONAVIR; RITUXIMAB; SESQUITERPENE DERIVATIVE; SESQUITERPENE LACTONE PARTHENOLIDE; TRITERPENOID; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RISK; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; EPIGENETICS; FEBRILE NEUTROPENIA; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LUNG SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; NEUROPATHIC PAIN; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

CONGRESSES AS TOPIC; EPIGENOMICS; HUMANS; LYMPHOMA, MANTLE-CELL; PROGNOSIS;

EID: 78651304015     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.532893     Document Type: Review

References (50)

1. Swerdlow SH, Habeshaw JA, Murray LJ, et al. Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. Am J Pathol 1983;113:181-197.
2. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992;16:637-640.
3. Williams ME, Westermann CD, Swerdlow SH. Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus. Blood 1990;76:1387-1391.
4. Rimokh R, Berger F, Cornillet P, et al. Break in the BCL1 locus is closely associated with intermediate lymphocytic lymphoma subtype. Genes Chromosomes Cancer 1990;2: 223-226.
5. Motokura T, Bloom T, Kim H, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991;350:512-515.
6. Williams ME, Swerdlow SH, Rosenberg CL, Arnold A. Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res 1992;52(Suppl.):5541s-5544s.
7. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-518.
8. Hoster E, Unterhalt M, Wörmann B, et al. The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lympho-ma: long term results of a randomized GLSG trial. Blood 2008;112(Suppl. 1):Abstract 3049.
9. Hoster E, Metzner B, Forstpointner R, et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood 2009;114(Suppl. 1):Abstract 880.
10. Hoster E, Hasford J, Hermine O, et al. Confirmation of the mantle cell lymphoma international prognostic index (MIPI) in an independent prospective patient cohort. Blood 2009;114(Suppl. 1):Abstract 138.
11. Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006;17:1418-1423.
12. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294-308.
13. Brody JD, Goldstein MJ, Czerwinski DK, Levy R. Immuno-transplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood 2009;113:85-94.
14. Brookes PS, Morse K, Ray D, et al. The triterpenoid 2-cyano-3,12- dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore. Cancer Res 2007;67:1793-1802.
15. Skalska J, Brookes PS, Nadtochiy SM, et al. Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide. PLoS One 2009;4:e8115.
16. Bernstein SH, Lin B, Hilchey S, et al. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives inhibit mitochondrial Lon protease activity: a potential novel pathway for the induction of lymphoma cell death. Blood 2009;114(Suppl. 1): Abstract 414.
17. Dewan MZ, Tomita M, Katano H, et al. An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells. Int J Cancer 2009;124:622-629.
18. Klier M, Anastasov N, Hermann A, et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008;22:2097-2105.
19. Yang GF, He WP, Cai MY, et al. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma. BMC Cancer 2010;10:133.
20. Li DW, Tang HM, Fan JW, et al. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol 2010;136: 997-1006.
21. Bea S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001;61:2409-2412.
22. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712-716.
23. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459:717-721.
24. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-130.
25. Boehm HS, Zhoa JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2006;129:1065-1079.
26. Wysocka J, Allis CD, Coonrod S. Histone arginine methyla-tion and its dynamic regulation. Front Biosci 2006;11:344-355.
27. Pal S, Baiocchi RA, Byrd JC, et al. Low levels of miR-92b\96 induce PRMT5 translation and H3R8/H4R3 methy-lation in mantle cell lymphoma. EMBO J 2007;15:3558-3569.
28. Yan F, Alinari L, Lustburg M, et al. Targeting the protein arginine methyltransferase 5 enzyme in glioblastoma multi-forme. Presented at the 101st Annual Meeting of the American Association for Cancer Research, 17-21 April 2010, Washington, DC: Abstract 1584.
29. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-15529.
30. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353: 1793-1801.
31. Wyczechowska D, Fabianowska-Majewska K. The effects of cladribine and fludarabine on DNA methylation in K562 cells. Biochem Pharmacol 2003;65:219-225.
32. Phillips JD, Pop I, Boucher K, Yu M. Up-regulation of miR-195 expression leads to decreased expression of basic fibroblast growth factor in CLL patients treated with DNA methylation inhibitors. Blood 2007;110(Suppl. 1):Abstract 3183.
33. Yu M, Epner E. The epigenetics of mantle cell lymphoma. Curr Treatment Options. Oncol 2007;8:375-381.
34. Spurgeon S, Yr M, Phillips JD, Epner E. Cladribine: not just another purine analogue? Expert Opin Invest Drugs 2009;18:1169-1181.
35. Inwards DJ, Hillman DW, Fishkin PA, et al. Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189). Blood 2006;108(Suppl. 1): Abstract 2746.
36. Beà S, Salaverria I, Armengol L, et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 2009;113:3059-3069.
37. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-9632.
38. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-843.
39. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435: 828-833.
40. Koralov SB, Muljo SA, Galler GR, et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008;132:860-874.
41. Ventura A, Young AG, Winslow MM, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008;132:875-886.
42. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008;9:405-414.
43. Opat S, Farinha P, Boyle M, et al. The percentage of cytotoxic T-cell in mantle cell lymphoma (MCL) biopsies predicts response to rituximab. Blood 2009;114(Suppl. 1):Abstract 2923.
44. Farinha P, Opat S, Boyle M, et al. Number of lymphoma-associated- macrophages (LAM) is an independent predictor of survival in patients with mantle cell lymphoma (MCL). Blood 2009;114(Suppl. 1):Abstract 3944.
45. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105:13520-13525.
46. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-197.
47. Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408-1418.
48. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:1555-1562.
49. Geyer S, Morton L, Habermann T, et al. Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lympho-ma: a population-based study. Cancer 2010;116:2993-3000.
50. Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immuno-chemotherapy: a European MCL intergroup study. Blood 2010;115:3215-3223.